11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

#obesity #type2diabetes #rarediseases #cancer #oncology #womenshealth #NovoNordisk #EliLilly #Lilly #GSK #severeasthma #JnJ #biologics #Otsuka #IgAN #kidneydisease #Sanofi #MS #BeOneMedicines #CLL #SLL #BMS #CELMoD #multiplemyeloma #Pfizer #breastcancer #CorceptTherapeutics #SGRA
zurl.co/xauLJ

Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer - PharmaTimes Ovarian cancer is the fifth leading cause of deaths from cancer in women

#oncology #womenshealth #CorceptTherapeutics #relacorilant #ovariancancer #cancerinwomen #cortisolmodulatingmedications #platinumresistantovariancancer #ROSELLAtrial #gynaecologicalcancerresearch #glucocorticoidreceptor #cortisolmodulatingtreatments
zurl.co/JWBM3

Ovarian cancer data restores faith in Corcept's relacorilant After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

After #CorceptTherapeutics setback with #relacorilant in Cushing syndrome last month, the company has bounced back with strong data in #ovariancancer, firming its share price.

pharmaphorum.com/news/ovarian...

FDA declines to approve Corcept's rare disorder drug As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to #CorceptTherapeutics with a decision not to approve #relacorilant, a drug for a rare #hormonaldisorder that causes #highbloodpressure.